340 related articles for article (PubMed ID: 15306588)
1. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.
Zeissig S; Bojarski C; Buergel N; Mankertz J; Zeitz M; Fromm M; Schulzke JD
Gut; 2004 Sep; 53(9):1295-302. PubMed ID: 15306588
[TBL] [Abstract][Full Text] [Related]
2. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients.
Epple HJ; Schneider T; Troeger H; Kunkel D; Allers K; Moos V; Amasheh M; Loddenkemper C; Fromm M; Zeitz M; Schulzke JD
Gut; 2009 Feb; 58(2):220-7. PubMed ID: 18936106
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution.
Heller F; Florian P; Bojarski C; Richter J; Christ M; Hillenbrand B; Mankertz J; Gitter AH; Bürgel N; Fromm M; Zeitz M; Fuss I; Strober W; Schulzke JD
Gastroenterology; 2005 Aug; 129(2):550-64. PubMed ID: 16083712
[TBL] [Abstract][Full Text] [Related]
4. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease.
Zeissig S; Bürgel N; Günzel D; Richter J; Mankertz J; Wahnschaffe U; Kroesen AJ; Zeitz M; Fromm M; Schulzke JD
Gut; 2007 Jan; 56(1):61-72. PubMed ID: 16822808
[TBL] [Abstract][Full Text] [Related]
5. Functional characterisation of decoy receptor 3 in Crohn's disease.
Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
[TBL] [Abstract][Full Text] [Related]
6. Disrupted barrier function through epithelial cell apoptosis.
Schulzke JD; Bojarski C; Zeissig S; Heller F; Gitter AH; Fromm M
Ann N Y Acad Sci; 2006 Aug; 1072():288-99. PubMed ID: 17057208
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction.
Li Q; Zhang Q; Wang M; Zhao S; Ma J; Luo N; Li N; Li Y; Xu G; Li J
Clin Immunol; 2008 Jan; 126(1):67-80. PubMed ID: 17964857
[TBL] [Abstract][Full Text] [Related]
8. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation.
Ma TY; Iwamoto GK; Hoa NT; Akotia V; Pedram A; Boivin MA; Said HM
Am J Physiol Gastrointest Liver Physiol; 2004 Mar; 286(3):G367-76. PubMed ID: 14766535
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.
Suenaert P; Bulteel V; Lemmens L; Noman M; Geypens B; Van Assche G; Geboes K; Ceuppens JL; Rutgeerts P
Am J Gastroenterol; 2002 Aug; 97(8):2000-4. PubMed ID: 12190167
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies.
Fries W; Muja C; Crisafulli C; Cuzzocrea S; Mazzon E
Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G938-47. PubMed ID: 18258792
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells.
Fischer A; Gluth M; Pape UF; Wiedenmann B; Theuring F; Baumgart DC
Am J Physiol Gastrointest Liver Physiol; 2013 Jun; 304(11):G970-9. PubMed ID: 23538493
[TBL] [Abstract][Full Text] [Related]
12. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
13. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications.
Mankertz J; Schulzke JD
Curr Opin Gastroenterol; 2007 Jul; 23(4):379-83. PubMed ID: 17545772
[TBL] [Abstract][Full Text] [Related]
14. Altered ENaC expression leads to impaired sodium absorption in the noninflamed intestine in Crohn's disease.
Zeissig S; Bergann T; Fromm A; Bojarski C; Heller F; Guenther U; Zeitz M; Fromm M; Schulzke JD
Gastroenterology; 2008 May; 134(5):1436-47. PubMed ID: 18355814
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional changes of the duodenum in human norovirus infection.
Troeger H; Loddenkemper C; Schneider T; Schreier E; Epple HJ; Zeitz M; Fromm M; Schulzke JD
Gut; 2009 Aug; 58(8):1070-7. PubMed ID: 19036950
[TBL] [Abstract][Full Text] [Related]
17. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.
Di Sabatino A; Pender SL; Jackson CL; Prothero JD; Gordon JN; Picariello L; Rovedatti L; Docena G; Monteleone G; Rampton DS; Tonelli F; Corazza GR; MacDonald TT
Gastroenterology; 2007 Jul; 133(1):137-49. PubMed ID: 17631138
[TBL] [Abstract][Full Text] [Related]
18. Moxibustion down-regulates colonic epithelial cell apoptosis and repairs tight junctions in rats with Crohn's disease.
Bao CH; Wu LY; Shi Y; Wu HG; Liu HR; Zhang R; Yu LQ; Wang JH
World J Gastroenterol; 2011 Dec; 17(45):4960-70. PubMed ID: 22174545
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options to modulate barrier defects in inflammatory bowel disease.
Hering NA; Schulzke JD
Dig Dis; 2009; 27(4):450-4. PubMed ID: 19897959
[TBL] [Abstract][Full Text] [Related]
20. Epithelial tight junctions in intestinal inflammation.
Schulzke JD; Ploeger S; Amasheh M; Fromm A; Zeissig S; Troeger H; Richter J; Bojarski C; Schumann M; Fromm M
Ann N Y Acad Sci; 2009 May; 1165():294-300. PubMed ID: 19538319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
